Advisors Preferred LLC Invests $73,000 in argenx SE (NASDAQ:ARGX)

Advisors Preferred LLC acquired a new position in shares of argenx SE (NASDAQ:ARGX) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 118 shares of the company’s stock, valued at approximately $73,000.

Other large investors have also modified their holdings of the company. Cromwell Holdings LLC boosted its stake in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after buying an additional 56 shares during the period. SG Americas Securities LLC boosted its position in shares of argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after buying an additional 21 shares during the period. Fulton Bank N.A. acquired a new stake in shares of argenx in the fourth quarter worth $226,000. Finally, Blue Trust Inc. boosted its position in shares of argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock worth $201,000 after buying an additional 298 shares during the period. 60.32% of the stock is owned by institutional investors.

argenx Stock Performance

argenx stock opened at $646.64 on Friday. The business’s 50-day simple moving average is $637.11 and its 200-day simple moving average is $576.94. The firm has a market capitalization of $39.29 billion, a PE ratio of -734.82 and a beta of 0.58. argenx SE has a 52 week low of $349.86 and a 52 week high of $678.21.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Robert W. Baird cut argenx from an “outperform” rating to a “neutral” rating and raised their target price for the stock from $515.00 to $650.00 in a research report on Friday, November 1st. Wedbush reaffirmed an “outperform” rating and issued a $655.00 target price on shares of argenx in a research report on Tuesday, December 3rd. Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Truist Financial reissued a “buy” rating and set a $700.00 price objective (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Finally, Piper Sandler lifted their price objective on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, argenx has a consensus rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.